KALA BIO Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Avi Minkowitz

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	6.4yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Oct 20

Kala Pharmaceuticals to execute reverse stock split

Kala Pharmaceuticals (NASDAQ:KALA) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s (KALA) issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. The split will reduce the number of shares of common stock outstanding from 73,208,140 shares to ~1,464,163 shares, subject to adjustment for the rounding up of fractional shares. The stock will will begin trading on a split-adjusted basis when the market opens on Friday, October 21, 2022. KALA shares are down over 2% premarket

Seeking Alpha • Aug 10

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.36 (+36.8% Y/Y) and the consensus Revenue Estimate is $2.02M (-33.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

CEO

Avi Minkowitz (37 yo)

less than a year

Görev süresi

Mr. Avi Minkowitz is CEO & CFO at KALA BIO, Inc. from February 2, 2026. He is Director of KALA BIO, Inc. from January 2026. Mr. Minkowitz serves as Director at International Star, Inc. since October 20, 20...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mary Reumuth	Treasurer & Secretary	12.3yrs	US$1.38m	Veri yok
Avi Minkowitz	CEO, CFO & Director	less than a year	Veri yok	Veri yok
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jill Steier	Executive Director of Investor Relations & Corporate Communications	4.8yrs	Veri yok	Veri yok
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	8.8yrs	Veri yok	Veri yok
Francis Mah	Chief Medical Advisor	3.2yrs	Veri yok	Veri yok
Josiah Craver	Senior VP & Corporate Controller	4.1yrs	Veri yok	Veri yok
Carl Rennie	Executive Director of Account Management	8yrs	Veri yok	Veri yok
Patrick Bedell	Executive Director of Trade & Alternate Channels	8yrs	Veri yok	Veri yok

6.4yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: KALA 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Avi Minkowitz	CEO, CFO & Director	less than a year	Veri yok	Veri yok
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Silverstein	Board Observer	10.1yrs	Veri yok	Veri yok
Peter Hutt	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ronald Krall	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bennett Shapiro	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Colin Gardner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Brendan Purdy	Independent Director	less than a year	Veri yok	Veri yok
Yonatan Colman	Independent Director	less than a year	Veri yok	Veri yok
Chaim Berger	Independent Director	less than a year	Veri yok	Veri yok
Hillel Posen	Independent Director	less than a year	Veri yok	Veri yok

0.3yrs

Ortalama Görev Süresi

41.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KALA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 14:07
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

KALA BIO, Inc. 7 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Biren Amin	Jefferies LLC
Christopher Neyor	J.P. Morgan

KALA BIO Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

Chairman notifies of intention to sell stock

KALA BIO, Inc. Announces Chief Executive Officer Changes

Recent updates

KALA BIO, Inc. announced delayed annual 10-K filing

Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent

Kala Bio Announces Launch Of First Commercial AI Product

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

Kala Bio, Inc. Receives Notice of Nasdaq Minimum Bid Price Non-Compliance

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $9.99909 million.

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO, Inc. announced delayed 10-Q filing

KALA BIO, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

KALA BIO, Inc. announced that it expects to receive $0.375 million in funding

KALA BIO, Inc. Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Financial position

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect

Chairman notifies of intention to sell stock

New major risk - Revenue and earnings growth

New major risk - Share price stability

New minor risk - Share price stability

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. announced that it has received $10.749667 million in funding

KALA BIO, Inc. announced that it expects to receive $10.749667 million in funding

New major risk - Share price stability

Price target decreased by 15% to US$16.50

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Consensus revenue estimates fall by 27%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Price target decreased to US$5.25

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları